CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether kidney transplant recipients who
receive belimumab (Benlysta®), combined with the standard of care medications for kidney
transplant recipients, is safe and effective in helping prevent new donor specific antibodies
(DSA) after transplantation. The presence of DSA increases the risk that the kidney
transplant recipient's body will reject the new kidney. The investigators are doing this
research because it is estimated that greater than 50% of kidney transplant failures are
attributed to antibodies produced in the body, that attack the transplanted organ as a
foreign object. DSA produced in the body after a kidney transplant, is thought to occur in
20-50% of patients and is associated with a low likelihood that the organ recipient's body
will accept the new kidney. A major unmet need in the kidney transplant area are safe and
effective therapies to prevent DSA after transplantation.